Oncology

  • 29 October 2019
    News

    Imfinzi combination improves survival in NSCLC patients

    AstraZeneca has reported that a combination of its drug Imfinzi (durvalumab) with chemotherapy improved progression-free survival (PFS) in the ongoing Phase III POSEIDON clinical trial involving treatment-naïve patients with stage...

Close
Close
Close

Go Top